Skip to main content

Events & Briefings

The Turning the Tide Against Cancer Through Sustained Medical Innovation initiative convenes and supports events to bring together members of the cancer community and foster dialogue and action around innovation in cancer care and research. Find out how you or your organization can get involved in our activities.

Upcoming Events

Turning the Tide Against Cancer National Conference 2014

Date: October 9, 2014
Location: Washington, D.C.

The Personalized Medicine Coalition, the American Association for Cancer Research, and Feinstein Kean Healthcare will be convening a second Turning the Tide Against Cancer Through Sustained Medical Innovation national conference to continue the ongoing dialogue around potential policy solutions that align with scientific advances and support innovation, while addressing the issue of rising health care costs.

The conference will include panel discussions, sessions and spotlight series by notable stakeholders and thought leaders in the cancer community to help identify specific policy pathways aimed at supporting the shift to patient-centered cancer research and care and addressing the value and cost of cancer care.

Learn how your organization can support the Turning the Tide Against Cancer national conference and get more information about the conference location and hotel.

Past Events

aacr-logo-x300

American Association for Cancer Research Annual Meeting 2014

Date: April 5–9, 2014
Location: San Diego, CA

The 105th Annual Meeting of the American Association for Cancer Research (AACR) will be held from April 5-9, 2014, in San Diego, California. AACR’s Annual Meeting provides an opportunity for members of the worldwide cancer research community to come together to learn about cutting-edge advances, obtain feedback on their own research, and make connections that can foster future collaborations.

Among the many basic, translational, and clinical discoveries to be presented at this year’s meeting, themed “Harnessing Breakthroughs – Targeting Cures,” there will be 10 educational and symposia sessions addressing key issues in regulatory science and policy, as well as three science policy sessions, one of which focuses on federal funding for cancer research and development.

Nearly 20,000 researchers, patient advocates, and other professionals in the cancer field from around the world are scheduled to be in attendance. To get more information, visit www.aacr.org.

Personalized Medicine Coalition

Personalized Medicine: How Medical Progress Happens

Date: July 22, 2013
Location: Washington, D.C.

The Personalized Medicine Coalition (PMC) held a briefing in collaboration with the Office of Senator Tom Carper (D-DE) to educate members of Congress about personalized medicine, in particular how it contributes to increasing quality and decreasing overall healthcare cost. The briefing included a panel of experts from across the personalized medicine community, including:

  • Patient, Stephanie Haney, Lung cancer patient
  • Drug Developer, Stephen L. Eck, M.D., Ph.D., Vice President Oncology Medical Sciences, Astellas Pharma Global Development
  • Diagnostics Developer, Patrick J. Balthrop, Sr., President and Chief Executive Officer, Luminex
  • Physician, Amy Abernethy, M.D., Director, Duke Center for Learning Health Care

Read the Personalized Medicine Coalition’s (PMC) Cost-containment and Deficit Reduction Policy Principles.

Turning the Tide Against Cancer National Conference 2012

Date: June 12, 2012
Location: Washington, D.C.

In 2012, the Personalized Medicine Coalition, American Association for Cancer Research, and Feinstein Kean Healthcare convened the inaugural Turning the Tide Against Cancer Through Sustained Medical Innovation national conference to discuss innovation in cancer care and research and identify ways to accelerate progress and build policies that will improve patient outcomes in an era of healthcare cost containment. View highlights from the conference, including photos and videos of the keynote presentations and panel discussions.